POINT Biopharma Global Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 4/6
POINT Biopharma Global has been growing earnings at an average annual rate of 58.2%, while the Biotechs industry saw earnings growing at 17.4% annually. Revenues have been growing at an average rate of 135.4% per year. POINT Biopharma Global's return on equity is 22.8%, and it has net margins of 39.6%.
Anahtar bilgiler
58.2%
Kazanç büyüme oranı
83.5%
EPS büyüme oranı
| Biotechs Sektör Büyümesi | 17.0% |
| Gelir büyüme oranı | 135.4% |
| Özkaynak getirisi | 22.8% |
| Net Marj | 39.6% |
| Son Kazanç Güncellemesi | 30 Sep 2023 |
Yakın geçmiş performans güncellemeleri
Güncelleme yok
Recent updates
POINT Biopharma Global Inc. (NASDAQ:PNT) Analysts Just Slashed This Year's Estimates
Aug 20
We Think POINT Biopharma Global (NASDAQ:PNT) Can Easily Afford To Drive Business Growth
Feb 01A Look At The Fair Value Of POINT Biopharma Global Inc. (NASDAQ:PNT)
Oct 18Point Biopharma plummets on announcing common stock offering
Sep 13POINT Biopharma Global GAAP EPS of -$0.27 misses by $0.05
Aug 12Gelir ve Gider Dağılımı
POINT Biopharma Global nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Sep 23 | 244 | 97 | 23 | 113 |
| 30 Jun 23 | 241 | 97 | 21 | 107 |
| 31 Mar 23 | 236 | 98 | 20 | 96 |
| 31 Dec 22 | 227 | 98 | 19 | 82 |
| 30 Sep 22 | 0 | -79 | 16 | 64 |
| 30 Jun 22 | 0 | -72 | 16 | 56 |
| 31 Mar 22 | 0 | -56 | 14 | 42 |
| 31 Dec 21 | 0 | -46 | 12 | 34 |
| 30 Sep 21 | 0 | -37 | 9 | 28 |
| 30 Jun 21 | 0 | -23 | 5 | 18 |
| 31 Mar 21 | 0 | -18 | 4 | 13 |
| 31 Dec 20 | 0 | -13 | 4 | 9 |
Kaliteli Kazançlar: PNT has high quality earnings.
Büyüyen Kar Marjı: PNT became profitable in the past.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: PNT's earnings have grown significantly by 58.2% per year over the past 5 years.
Büyüme Hızlandırma: PNT has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Kazançlar vs. Sektör: PNT has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).
Özkaynak Getirisi
Yüksek ROE: PNT's Return on Equity (22.8%) is considered high.